New Zealand's PHARMAC is seeking input on a proposal to list GSK's Tivicay (dolutegravir) for the treatment of HIV, as well as amend the listing of the currently funded HIV treatment Kivexa (abacavir sulphate with lamivudine).
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Sep 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Sep 16
